MET and breast carcinoma: As shown in Figure 1A, high expression of c-Met (MET+) correlated with expression of CSC markers, ALDH1A1 (p < 0.001), ALDH1A3 (p < 0.001), and CD133 (p < 0.001) in breast cancers.